Navigation Links
Avalon Pharmaceuticals Announces Positive Interim Results For,AVN944 Phase I Trial

the slides, please choose the 'listen via phone' option to view the slides in real time as there is a 30 second delay otherwise. The conference call replay will be available through August 15, 2007 on Avalon's website (www.avalonrx.com).

About Avalon Pharmaceuticals

Avalon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of potential first-in-class cancer therapeutics. Avalon has a lead product in Phase I clinical development (AVN944), preclinical programs to develop inhibitors for the Beta-catenin and Aurora pathways, discovery programs for Survivin and Myc pathway inhibitors, and value generating partnerships with Merck, MedImmune, Medarex, and Novartis. By utilizing AvalonRx(R) our platform technology, based upon the proprietary use of large-scale gene expressions, we are uniquely positioned to develop therapeutics focused on pathways that have historically been characterized as "undruggable". Avalon was established in 1999 and is headquartered in Germantown, Md.

About AvalonRx(R)

AvalonRx(R) is a comprehensive, innovative and proprietary suite of technologies based upon large-scale gene expression analysis. This platform facilitates drug discovery by expanding the range of therapeutic targets for drug intervention, including targets and target pathways frequently considered intractable using conventional HTS approaches, allows more informed decisions about which compounds to advance towards clinical trials, and facilitates drug development through identification of biomarkers of efficacy that can stratify patients or provide early indicators of response.

Safe Harbor Statement

This announcement contains, in addition to historical information, certain forward-looking statements that involve risks and uncerta
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
2. Avalon Pharmaceuticals to Present at the American Association for Cancer Research 2007 Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Highest Rate of TB Infection in U.S., SAN ... of tuberculosis (TB) in the U.S., with recurrent outbreaks ... recent study on,homelessness and TB by Harvard Medical School. ... San Francisco. To address this health care,crisis, St. Anthony,s ...
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... of the National Institutes of Health,has started ... for patients with,metastatic melanoma using systemic administration ... reovirus. The trial is,being carried out by ...
Cached Medicine Technology:National Healthcare for Homeless Day: August 13th, 2008 2U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R) 2
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... -- Researchers from The Miriam Hospital have ... (COPD) who are also depressed have difficulty sticking ... be particularly true for women, and screening and ... part of treatment. The study and its findings ... . , Chronic obstructive pulmonary disease is ...
(Date:7/9/2014)... KNOXVILLEAmphibian declines and extinctions around the world have ... chytridiomycosis, but new research from the National Institute ... another pathogen, ranavirus, may also contribute. , ... that ranavirus, which causes severe hemorrhage of internal ... populations of wood frogs if they are exposed ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... allergic diseases has risen dramatically in Western societies. One ... to microorganisms and have fewer infections than previous generations, ... study by researchers at Sahlgrenska Academy, University of Gothenburg, ... maturation of the immune system in relation to allergic ... of the Vstra Gtaland Region, half of them on ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... APS Healthcare, a leading provider of specialty healthcare solutions, ... Services to deliver a unified total population health management ... the State consolidated its service providers from three to ... population that APS has been serving for the past ...
... PROSPECT, Ill., May 5 The National Association of ... May 5, 2009, examining the flagrant lawlessness of Web ... why this ,wild west, of an electronic marketplace is ... dead and injured patients," the paper asserts. The "State ...
... May 5 Tim Wentworth, group president, employer accounts, Medco ... to address the Bank of America/Merrill Lynch 2009 Health Care ... at the Palace Hotel in New York City, will begin ... officer, is also scheduled to attend.The presentation may be heard ...
... in one Minnesota city , , TUESDAY, May 5 (HealthDay ... known, another learning disability -- the inability to write ... new study suggests. , So-called written-language disorder is a ... epidemiologist at the Mayo Clinic and lead author of ...
... with elevated albumin levels were more likely to get ... News) -- A higher-than-normal level of the protein albumin ... clots in the deep veins of the lungs and ... (VTEs) include deep vein thrombosis (DVT), a clotting in ...
... NIH and Robert Wood Johnson Foundation-Sponsored Study Focuses on ... 5 Nearly 75 percent of children ages 3-6 ... getting enough exercise. A focus group study of child ... several reasons children are not getting as much physical ...
Cached Medicine News:Health News:Ohio Selects APS Healthcare to Manage Unified Population Health Management Program for State Employees 2Health News:NABP Position Paper Calls for Action Against Proliferation of Rogue Internet Drug Outlets 2Health News:NABP Position Paper Calls for Action Against Proliferation of Rogue Internet Drug Outlets 3Health News:Medco to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:Writing Disorder May Be Common Among Kids 2Health News:Urine Test Predicts Vein Clot Risk 2Health News:Urine Test Predicts Vein Clot Risk 3Health News:ABCs and No Skinned Knees: Study Reveals Various Barriers to Physical Activity in Child Care 2Health News:ABCs and No Skinned Knees: Study Reveals Various Barriers to Physical Activity in Child Care 3
Preclude Dura Substitute is the only non-biological membrane designed to "seal" around suture holes. 0.3 mm as nominal thickness....
... synthetic absorbable implant for the bridging of Dura ... is pliable, regardless of being used dry or ... must be taken, while implanting, to ensure that ... is oriented towards the cortex or the spinal ...
... is a non-absorbable dura ... purified polyesterurethane. Its microporous ... of fibroblast, supporting tissue ... minimizes suture channels, resulting ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Medicine Products: